Outlook’s wet AMD treatment accepted by SMC for NHS Scotland
The endorsement for Lytenava is based on the outcomes from the company’s clinical programme.
Drug Development
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
Aytu BioPharma to commercialise Exxua for MDD in the US
SCHOTT Pharma invests in RTU cartridge capacity expansion
EC authorises Sydnexis’ paediatric myopia treatment
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Axxam and Molecular Health link for therapeutic targets
Redwire gains Aspera contract for space-based cancer research
